Alebund Pharmaceuticals (Jiangsu) Limited (HKG:9637)
Hong Kong · Delayed Price · Currency is HKD 28.80
+0.30 (1.05%)
At close: Sep 4, 2026
HKG:9637 Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 |
|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 |
Cash & Equivalents | 1,345 | 358.33 | 343.77 |
Short-Term Investments | 49.5 | 28.22 | 22.4 |
Trading Asset Securities | - | 145.46 | - |
Cash & Short-Term Investments | 1,394 | 532 | 366.17 |
Cash Growth | - | 45.29% | - |
Accounts Receivable | 0.36 | - | 0.87 |
Other Receivables | 5.37 | 0.68 | 7.4 |
Receivables | 5.72 | 0.68 | 14.12 |
Inventory | 14.09 | 10.27 | 6.12 |
Other Current Assets | 2.61 | 15.77 | 2.37 |
Total Current Assets | 1,416 | 558.72 | 388.78 |
Property, Plant & Equipment | 592.96 | 612.94 | 628.04 |
Long-Term Investments | 44.72 | 66.64 | 3.26 |
Other Intangible Assets | 8.62 | 9.04 | 10.39 |
Other Long-Term Assets | 101.23 | 92.6 | 78.68 |
Total Assets | 2,164 | 1,340 | 1,109 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 |
|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 |
Accounts Payable | 60.57 | 67.77 | 25.88 |
Accrued Expenses | 13.29 | 21.32 | 18.43 |
Current Portion of Long-Term Debt | 17.93 | - | 28 |
Current Portion of Leases | 2.44 | 3.69 | 3.69 |
Current Unearned Revenue | - | 67.2 | - |
Other Current Liabilities | 50.15 | 79.85 | 1,868 |
Total Current Liabilities | 144.38 | 239.83 | 1,944 |
Long-Term Debt | 555.82 | 545.33 | 445.3 |
Long-Term Leases | 0.46 | 0.4 | 2.16 |
Long-Term Unearned Revenue | 54.12 | 49.2 | 40.31 |
Other Long-Term Liabilities | 0.62 | 1.94 | 18.6 |
Total Liabilities | 755.39 | 836.69 | 2,450 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 |
|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 |
Common Stock | 339.85 | 283.1 | 153.62 |
Retained Earnings | - | -1,365 | -1,165 |
Comprehensive Income & Other | 1,069 | 1,585 | -319.04 |
Total Common Equity | 1,409 | 503.24 | -1,330 |
Minority Interest | - | - | -10.81 |
Shareholders' Equity | 1,409 | 503.24 | -1,341 |
Total Liabilities & Equity | 2,164 | 1,340 | 1,109 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 |
|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 |
Total Debt | 576.64 | 549.42 | 479.15 |
Net Cash (Debt) | 817.36 | -17.42 | -112.98 |
Net Cash Growth | - | - | - |
Net Cash Per Share | 3.00 | -0.07 | -0.42 |
Filing Date Shares Outstanding | 339.85 | 283.1 | 271.6 |
Total Common Shares Outstanding | 339.85 | 283.1 | 271.6 |
Working Capital | 1,272 | 318.89 | -1,555 |
Book Value Per Share | 4.14 | 1.78 | -4.90 |
Tangible Book Value | 1,400 | 494.2 | -1,341 |
Tangible Book Value Per Share | 4.12 | 1.75 | -4.94 |
Buildings | - | 392.08 | 377.69 |
Machinery | - | 239.81 | 230.31 |
Construction In Progress | - | 2.32 | 1.24 |
Leasehold Improvements | - | 16.15 | 15.8 |